相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design and Synthesis of Bis-Biotin-Containing Reagents for Applications Utilizing Monoclonal Antibody-Based Pretargeting Systems with Streptavidin Mutants
D. Scott Wilbur et al.
BIOCONJUGATE CHEMISTRY (2010)
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
Steven I. Park et al.
BLOOD (2010)
The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-Particles
Tom Back et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M. Pagel et al.
BLOOD (2009)
Glomerular Filtration Rate After Alpha-Radioimmunotherapy with 211At-MX35-F(ab′)2: A Long-Term Study of Renal Function in Nude Mice
Tom Back et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia
John M. Pagel et al.
CANCER RESEARCH (2009)
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
Emma Y. Song et al.
CANCER BIOLOGY & THERAPY (2008)
Radioimmunotherapeutic approaches for leukemia: the past, present and future
J. M. Pagel
CYTOTHERAPY (2008)
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
John M. Pagel et al.
BLOOD (2008)
Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate
Jostein Dahle et al.
BLOOD (2007)
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells
Claudia Friesen et al.
CANCER RESEARCH (2007)
Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators
Christophe Antczak et al.
BIOCONJUGATE CHEMISTRY (2006)
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted Radioimmunotherapy of hematologic malignancies
YK Lin et al.
CANCER RESEARCH (2006)
Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
JS Jaggi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
JM Pagel et al.
BLOOD (2006)
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
DM Goldenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Renal tubulointerstitial changes after internal irradiation with α-particle-emitting actinium daughters
JS Jaggi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55:: results of a phase I-II study
M Ringhoffer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases
S Nilsson et al.
CLINICAL CANCER RESEARCH (2005)
Cancer radioimmunotherapy with alpha-emitting nuclides
O Couturier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
JM Burke et al.
BONE MARROW TRANSPLANTATION (2003)
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
JM Pagel et al.
BLOOD (2003)
Pretarget radiotherapy with an anti-CD25 antibody streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
ML Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters
T Waldmann
LEUKEMIA & LYMPHOMA (2003)
Pretargeting radioinimunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213
ML Zhang et al.
BLOOD (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation:: Biodistribution, biokinetics and immediate toxicities
I Buchmann et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2002)
Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma
S Supiot et al.
CANCER (2002)
Tumor therapy with targeted atomic nanogenerators
MR McDevitt et al.
SCIENCE (2001)
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome:: results of a phase I-II study
D Bunjes et al.
BLOOD (2001)
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
DB Axworthy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
